The Safety and Effectiveness of Tocilizumab in Rheumatoid Arthritis

Phase

N/A

Condition

Joint Injuries

Rheumatoid Arthritis

Treatment

N/A

Clinical Study ID

NCT04384068

HS-1383

Ages 18-100
All Genders

Study Summary

The aim of this study is to investigate the safety and effectiveness of tocilizumab (Actemra®) using Chinese Rheumatology Information Platform (CRIP) on Chinese Rheumatology Data Centre (CRDC, http://www.crdc.org.cn/) in Chinese RA patients.

Eligibility Criteria

Inclusion

Inclusion Criteria:

Patients at least 18 years of age.
Patients with a diagnosis of RA according to the revised (2010) ACR criteria.
Patients per treating physician's judgment to treat with Tocilizumab.
Signed written informed consent

Exclusion

Exclusion Criteria:

Patients are receiving or have received any investigational agent 4 weeks (or 5half-lives of investigational agent, whichever is longer) prior to enrollment of thisstudy.
Subjects with contra-indications to Tocilizumab therapy as detailed in the label (withknown hypersensitivity to Tocilizumab or accessories; or with active infections.).

Study Design

December 27, 2018

January 31, 2022

Study Description

Tocilizumab (Actemra®) is a humanized monoclonal antibody targeting the human IL-6 receptor, which inhibits the binding of this cytokine to its receptor. It is the first monoclonal antibody developed for RA treatment with this mechanism of action and has been approved by regulatory authorities in China since 2013. Data from five phase III studies with over 4000 recruited patients have shown that tocilizumab at a dose of 8 mg/kg, in combination with methotrexate/DMARDs or as monotherapy, can produce a quick and clinically relevant improvement in RA signs and symptoms, health status, and prevent joint damage, for both patients who have not been previously treated with and refractory to methotrexate, other DMARDs or anti-TNF agents. However, in real-world clinical setting, the safety profile and treatment pattern with regard to the persistence on tocilizumab and the efficacy are not clear in China. The aim of this study is to investigate the safety and effectiveness of tocilizumab using Chinese Rheumatology Information Platform (CRIP) on Chinese Rheumatology Data Centre (CRDC, http://www.crdc.org.cn/) in Chinese RA patients.

Connect with a study center

Peking Union Medical College Hospital
Beijing, Beijing 100005
China
Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.